Beam Looks Beyond Liver With Guide Therapeutics Acquisition
Company Pays $120m Upfront
Executive Summary
You may also be interested in...
Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Bluebird Sickle Cell Gene Therapy Hangs In Balance
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
Ensoma Launches With Takeda Partnership On Myeloablation-Free Gene Therapy
The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports